FDA cites Genentech plant after inspections; Vectibix trial enrollment stopped on outcomes;

@FiercePharma: Shanghai Pharma's ex-CEO gets suspended death sentence in bribery/graft case. If he behaves, he'll get life in prison. News | Follow @FiercePharma

> FDA inspectors cited Genentech for shortfalls at a San Francisco, CA, plant after 13 visits this year. Story

> Researchers stopped recruiting patients for a trial of Amgen's Vectibix in stomach and esophageal cancer after patients receiving the drug saw inferior outcomes. News

> The former CEO of state-owned Shanghai Pharmaceutical got a suspended death sentence in a corruption case that included charges of accepting bribes and embezzling public funds. Report

> Salix Pharmaceuticals agreed to buy Oceana Therapeutics for $300 million to get access to the latter's bowel-control and bladder drugs. Item

> Lundbeck's Q3 sales grew by 10% to 3.98 billion kronor ($729 million), despite 12% drop in Lexapro sales; antidepressant has generic rivals in three European countries. News

> Roche's experimental skin cancer drug vismodegib won priority review from the FDA as a treatment for patients with advanced basal cell carcinoma that can't be treated with surgery. Article

> Piper Jaffray analysts gave Vertex Pharmaceuticals a new, lower price target of $56, while Robert W. Baird downgraded shares to "neutral" and cut their price target to $33 from $62. Story

> Sinopharm plans to raise $1.5 billion to $2 billion from a Hong Kong IPO during the first half of 2012. More

Biotech News

@FierceBiotech: Alkermes keeps drug-delivery ties intact in Lilly-Amylin breakup. Article | Follow @FierceBiotech

@JohnCFierce: Startup Rhythm (Boston) gets Merck development vet Keith M. Gottesdiener as new CEO. Release | Follow @JohnCFierce

@RyanMFierce: Mylan is buying Pfizer's respiratory drug delivery tech. Release focus is on COPD. | Follow @RyanMFierce

@MaureenFierce: Chuck Norris (yes, Chuck Norris) is the newest anti-vaccine activist. Celebrities + science = fun! More | Follow @MaureenFierce

> Hot Ablynx antibody tech earns $69M discovery pact with Merck Serono. Story

> Fledgling Rhythm recruits Merck vet to helm the Boston biotech. Report

Medical Device News

> Pivot secures $32M in Series C. Piece

> FDA clears Cordis' Empira catheters. Item

Drug Delivery News

> Sunovion's inhaled steroid for allergies looks good in Ph3 amid FDA review. More

> Alkermes keeps drug-delivery ties intact in Lilly-Amylin breakup. Story

> Bioject axes 38% of staff as needle-free biz faces revenue, FDA hurdles. Article

> Neuroderm reportedly sees promising data for Parkinson's drug patch. Report

And Finally... Wal-Mart looks for partners for aggressive push into primary healthcare. News

Suggested Articles

Gilead Sciences has found a new chief financial officer in an appointment that has mergers and acquisitions written all over it.

Pfizer's role as the hero in ramping up production of a chemo drug badly needed by pediatric oncologists is a turnabout for the drugmaker.

Johnson & Johnson is dealing with $2 billion in patent losses in 2019, but has 10 drugs growing at double-digit percentages, executives said Tuesday.